Home
Filipino
English தமிழ் Português 中文 Tiếng Việt Filipino ਪੰਜਾਬੀ Awtomatikong pagsasalin — ang bersyong Ingles ang siyang opisyal.

Mga Gamot na GLP-1 (Ozempic, Wegovy) at ang Iyong Operasyon Impormasyon

Ang pahinang ito ay isinalin ng makina at hindi pa nasusuri ng isang doktor. Ang bersyong Ingles ang siyang opisyal.

Ano ang gamot na ito

Ang mga gamot na GLP-1 ay isang grupo ng mga gamot na maaaring kilala mo sa mga brand name gaya ng Ozempic o Wegovy. Ang kanilang medikal na pangalan ay GLP-1 receptor agonists, na nangangahulugang ginagaya nito ang isang natural na hormone sa iyong katawan. Ginagamit ito ng mga tao sa dalawang pangunahing dahilan: upang pamahalaan ang type-2 diabetes at upang magbawas ng timbang.

Sa iyong katawan, ang mga gamot na ito ay gumagana sa dalawang paraan. Binabawasan nito ang iyong gana sa pagkain, kaya nababawasan ang iyong kagustuhang kumain. Pinababagal din nito ang bilis ng pag-ubos ng laman ng iyong tiyan, kaya mas matagal nananatili ang pagkain sa iyong tiyan at mas mabilis kang nabubusog. Ito ang dahilan kung bakit karaniwang epekto nito ang pagbaba ng timbang.

Kung gumagamit ka ng isa sa mga gamot na ito at nagpaplano ka ng operasyon, mahalaga ito para sa iyong surgical team. Ang mga gamot na ito ay nagiging mas karaniwan, kaya mas maraming pasyente ang nakikita ng mga surgeon na gumagamit nito malapit sa oras ng operasyon [1]. Ang isang dahilan kung bakit ito mahalaga ay ang epekto nito sa iyong tiyan: dahil mas mabagal ang pag-ubos ng pagkain, kailangang malaman ito ng iyong anaesthetic team kapag pinaplano ang iyong pangangalaga [2].

Ang pananaliksik tungkol sa mga gamot na ito at joint replacement surgery ay patuloy pang lumalago. Iminumungkahi ng ilang pag-aaral ang mga posibleng benepisyo, gaya ng mas mababang panganib ng impeksyon pagkatapos ng hip o knee replacement [3], habang ang ibang mga natuklasan ay magkakaiba at kailangan pa ng higit pang pananaliksik [4]. Wala pang isang pinal na konklusyon.

Hindi mo kailangang itigil ang iyong gamot bago ang operasyon nang mag-isa. Ang kasalukuyang payo ay hindi inirerekomenda ang pagtigil sa mga gamot na ito bago ang isang procedure, dahil maaari nitong maapektuhan ang kontrol ng iyong blood sugar at ang iyong timbang [5]. Ang iyong team ay makikipag-usap sa iyo tungkol sa iyong partikular na plano.

Paano ito nakakaapekto sa iyong operasyon at anaesthetic

Ang pangunahing dapat malaman ay tungkol sa iyong tiyan. Pinababagal ng mga gamot na ito kung gaano kabilis mabakante ang iyong tiyan. Nangangahulugan ito na ang pagkain ay maaaring manatili doon nang mas matagal kaysa sa inaasahan, kahit na nag-fasting ka na. Kung ikaw ay sedated habang isinasagawa ang iyong operasyon, ang mga nilalaman ng tiyan ay maaaring bumalik pataas at pumasok sa iyong mga baga. Tinatawag itong aspiration. Ito ay isang kilalang panganib sa anumang anaesthetic, at ang mga gamot na ito ay maaaring makadagdag dito.

Maingat itong pinamamahalaan ng iyong anaesthetic team. Sinusunod nila ang mga alituntunin tungkol sa paghinto ng gamot bago ang iyong operasyon at tungkol sa pag-fasting nang mas matagal kaysa sa karaniwan. Ang ilang mga team ay sinusuri rin ang iyong tiyan gamit ang ultrasound scan bago ang procedure, upang makita kung may pagkain o likido pa ring nananatili doon. Natuklasan ng mga pag-aaral na karamihan sa mga taong gumagamit ng mga gamot na ito ay may natitirang pagkain o likido sa tiyan, kahit na pagkatapos ng normal na fasting [1]. Kung ito ay talagang humahantong sa pagpasok ng pagkain o likido sa mga baga ay hindi gaanong malinaw, at ang pananaliksik sa puntong iyon ay hindi pare-pareho [1].

Mayroon ding ilang nakapagpapalakas-loob na balita tungkol sa paggaling. Ang mga pag-aaral sa mga taong sumasailalim sa hip o knee replacement ay nakatuklas na ang mga gumagamit ng mga gamot na ito sa panahon ng operasyon ay walang pare-parehong pagtaas sa pangangailangan para sa karagdagang operasyon sa short term [2]. Nakatuklas din ang ilang pag-aaral ng mas mababang panganib ng impeksyon pagkatapos ng operasyon [2]. Para sa operasyon sa kamay tulad ng carpal tunnel release, isang pag-aaral ang nakatuklas ng maliit na pagbaba sa mga problema sa paghilom ng sugat, at walang pagtaas sa iba pang mga komplikasyon sa unang 90 araw [3].

Ang iyong team ay nagtutulungan upang planuhin ito kasama ka. Kasama rito ang iyong surgeon, ang iyong anaesthetist, at kung kinakailangan, ang doktor na namamahala sa iyong diabetes. Ang layunin ay isang planong iniangkop para sa iyo, upang ang iyong gamot, ang iyong mga instruksyon sa fasting, at ang iyong operasyon ay lahat na magtugma nang ligtas. Patuloy pa ring hinahanap ng mga mananaliksik ang pinakamahusay na paraan ng pag-aalaga sa mga taong gumagamit ng mga gamot na ito bago ang operasyon [4], kaya ang iyong team ay mananatiling updated at kakausapin ka tungkol sa eksaktong dapat gawin bago ang iyong operasyon.

Ang dapat mong gawin

Kung ikaw ay gumagamit ng GLP-1 medication at nagpaplano ng operasyon, ipaalam ito sa lahat ng kasangkot sa iyong pangangalaga. Kabilang dito ang iyong surgeon, iyong anaesthetist, at iyong GP. Makakatulong din ang pagsabi sa doktor na nagreseta ng gamot, dahil sila ang namamahala sa iyong diabetes o weight plan at magiging bahagi ng desisyon.

Huwag itigil ang pag-inom ng iyong gamot nang mag-isa. Kung sa tingin mo ay kailangan itong ihinto pansamantala, itanong muna sa doktor na nagreseta nito. Ang pagtigil nito nang walang payo ay maaaring makaapekto sa iyong blood sugar at iyong timbang.

Bibigyan ka ng iyong team ng malinaw na mga instruksyon bago ang iyong operasyon. Maaaring saklaw nito kung dapat bang ihinto pansamantala ang gamot, at kung gaano ito katagal. Sasaklawin din nito ang fasting, na maaaring mas matagal kaysa sa karaniwan dahil pinapabagal ng mga gamot na ito ang iyong tiyan. Sundin ang mga instruksyong iyon nang eksakto ayon sa nakasulat.

Ang iyong pangangalaga ay pinaplano bilang isang team. Dahil naaapektuhan ng mga gamot na ito kung paano nababakante ang iyong tiyan, ang iyong surgeon at anaesthetist ay nagtutulungan kasama ang doktor na namamahala sa iyong diabetes upang bumuo ng planong angkop para sa iyo [1]. Patuloy pa ring pinag-aaralan ng mga researcher ang pinakamahusay na paraan ng pangangalaga sa mga taong gumagamit ng mga gamot na ito bago at pagkatapos ng operasyon [2], kaya pananatilihing updated ang iyong team.

Kung mayroong hindi malinaw, magtanong. Walang tanong tungkol sa iyong gamot ang masyadong maliit kapag may kinalaman sa operasyon.

Mga Sanggunian

[1] The Impact of Glucagon-Like Peptide-1 Agonists on Hip and Knee Arthroplasty and Perioperative Considerations. The Journal of Arthroplasty. 2024. DOI: 10.1016/j.arth.2023.12.002

[2] Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia. The Korean Journal of Internal Medicine. 2026. DOI: 10.3904/kjim.2025.277

[3] Glucagon-like peptide-1 receptor agonists in total joint arthroplasty: a comprehensive systematic review of what orthopaedic surgeons should know. Arthroplasty. 2026. DOI: 10.1186/s42836-026-00375-w

[4] Impact of Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes in Arthroplasty: A Systematic Review. The Journal of Arthroplasty. 2025. DOI: 10.1016/j.arth.2025.07.015

[5] Periprocedural use of GLP-1 receptor agonists: ANZCA Clinical Practice Recommendations. ANZCA. 2025.

[6] Perioperative anesthesia management of GLP-1 receptor agonists: a systematic review of potential risks. Perioperative Medicine. 2026. DOI: 10.1186/s13741-026-00662-9

[7] Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release. Journal of Hand Surgery Global Online. 2025. DOI: 10.1016/j.jhsg.2025.100746

[8] GLP-1 agonists: a new hope for patients, a new challenge for anaesthetists. Anaesthesiology Intensive Therapy. 2025. DOI: 10.5114/ait/203167

Reviewed by Kieran Hirpara · 13 June 2026.

Want the clinical detail? Read the clinician version.

Talk to your treating clinician for advice specific to you.

For an appointment with the CQ Hand + Upper Limb team, ask your GP about a referral or visit www.cqupperlimb.com.

Evidence & references

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Overview

  • Glucagon-like peptide-1 receptor agonists induce delayed gastric emptying [1].
  • The pharmacological mechanisms of GLP-1 RA-induced delayed gastric emptying have clinical implications for perioperative aspiration risk during anesthesia [1].
  • Interdisciplinary collaboration between endocrinologists and anesthesiologists is emphasized for safe and individualized perioperative management of patients on GLP-1 RAs [1].
  • GLP-1 agonists may not produce sufficient weight loss to achieve body mass index cutoffs for total joint arthroplasty depending on individual patient factors, including starting bodyweight [2].
  • Further high-quality studies are called for to address the optimal perioperative care of patients on GLP-1RAs due to their increasing popularity in patients with obesity [3].
  • Conflicting findings in the literature highlight the need for further research, particularly well-designed multicenter studies and randomized controlled trials, to clarify the effects of GLP-1 RAs on surgical outcomes [4].
  • Arthroplasty surgeons will encounter an increasing number of patients on GLP-1 agonists [5].
  • It is important for arthroplasty surgeons to understand the implications of GLP-1 agonist use in the perioperative period [5].
  • GLP-1 agonist use should not be a contraindication for proceeding with total shoulder arthroplasty based on data showing no association with adverse events following shoulder surgery [6].
  • Elective preprocedural cessation of GLP-1RAs and GLP-1/GIPRAs is not recommended due to insufficient data supporting cessation and risks of hyperglycaemia and compromised weight control [7].
  • The variability in available studies, potential confounding factors, and severe heterogeneity of conclusions emphasize the need for more high-quality evidence-based primary research to optimize perioperative management of patients taking GLP-1 RAs [8].
  • GLP-1 agonists have effects on bone health that are relevant to perioperative patients undergoing orthopedic surgery, with an emphasis on spine surgery [9].
  • GLP-1RA use suggests a potential benefit for optimizing high-risk patients who have obesity or diabetes undergoing total joint arthroplasty [10].

Effects on Surgery and Recovery

Perioperative Anesthesia and Gastric Emptying

  • Authors call for further high-quality studies to address the optimal perioperative care of patients on GLP-1RAs due to their increasing popularity in patients with obesity [3].
  • Available observational evidence suggests that extended GLP-1 RA withholding, 24-hour clear liquid diets, and pre-procedural gastric POCUS may be associated with reduced residual gastric content in selected patient populations [14].

Arthroplasty Outcomes

  • Arthroplasty surgeons will encounter an increasing number of patients on GLP-1 agonists, making it important to understand the implications of their use in the perioperative period [5].
  • Conflicting findings highlight the need for further research, particularly well-designed multicenter studies and randomized controlled trials, to clarify the effects of GLP-1 RAs on surgical outcomes in arthroplasty [4].
  • Findings suggest a potential benefit of GLP-1RA use for optimizing high-risk patients who have obesity or diabetes undergoing total joint arthroplasty [10].
  • While GLP-1 receptor agonists show potential to reduce postoperative complications in total joint arthroplasty, findings remain inconsistent, and further research is needed to clarify their impact on outcomes and establish perioperative management guidelines [11].
  • Preoperative glucagon-like peptide-1 receptor agonist use may be linked to reduced readmission risk following joint arthroplasty, without evidence of increased postoperative medical harm [12].
  • Semaglutide and other GLP-1 agonists may increase the number of eligible candidates for elective total joint arthroplasty by enabling weight loss and improving diabetic control [13].
  • Semaglutide and other GLP-1 agonists may potentially reduce postoperative complications such as sepsis and prosthetic joint infections [13].
  • Current observational data suggest that perioperative GLP-1 RA use in patients undergoing total hip or knee arthroplasty is not associated with a consistent increase in short-term revision rates [16].
  • Current observational data suggest that perioperative GLP-1 RA use in patients undergoing total hip or knee arthroplasty may be associated with a reduced risk of postoperative infection [16].

Other Orthopedic Procedures

  • Based on data from a systematic review and meta-analysis, GLP-1 agonist use should not be a contraindication for proceeding with total shoulder arthroplasty [6].
  • Perioperative GLP-1RA use was associated with a small yet statistically significant reduction in the odds of wound dehiscence following carpal tunnel release [15].
  • Perioperative GLP-1RA use did not increase the odds of any other 90-day postoperative complications following carpal tunnel release [15].

Bone Health

  • A narrative review explores the mechanisms of action of GLP-1 agonists, their effects on bone health, and the implications of their use in perioperative patients undergoing orthopedic surgery, with an emphasis on spine surgery [9].
  • Exenatide is the best option agent with regard to the risk of fracture [17].

Practical Considerations

Perioperative Anesthesia and Gastric Emptying

  • Delayed gastric emptying induced by GLP-1 RAs has implications for perioperative aspiration risk during anesthesia [1].

Medication Management

Arthroplasty Outcomes and Eligibility

  • Conflicting findings highlight the need for further research, particularly well-designed multicenter studies and randomized controlled trials, to clarify the effects of GLP-1 RAs on surgical outcomes [4].

Shoulder Surgery

Bone Health and Spine Surgery

Key Evidence

  • [L4] This review summarizes the pharmacological mechanisms and clinical implications of GLP-1 RA-induced delayed gastric emptying, evaluates current literature on perioperative aspiration risk, and emphasizes the importance of interdisciplinary collaboration between endocrinologists and anesthesiologists to ensure safe and individualized perioperative management. [1] (10.3904/kjim.2025.277)
  • [Paper] While efficacious, GLP-1 agonists may not produce sufficient weight loss to achieve body mass index cutoffs for total joint arthroplasty depending on individual patient factors, including starting bodyweight. [2] (10.2106/jbjs.rvw.23.00167)
  • [L4] Due to the increasing popularity of GLP-1RAs in patients with obesity, the authors call for further high-quality studies to address the optimal perioperative care of patients on GLP-1RAs. [3] (10.5114/ait/203167)
  • [L4] However, conflicting findings highlight the need for further research, particularly well-designed multicenter studies and randomized controlled trials, to clarify the effects of GLP-1 RAs on surgical outcomes. [4] (10.1016/j.arth.2025.07.015)
  • [L5] Arthroplasty surgeons will encounter an increasing number of patients on GLP-1 agonists, making it important to understand the implications of their use in the perioperative period. [5] (10.1016/j.arth.2023.12.002)
  • [L1] Based on this data, GLP-1 agonist use should not be a contraindication for proceeding with TSA. [6] (10.1016/j.jse.2025.12.005)
  • [L2] The variability in available studies, potential confounding factors, and the severe heterogeneity of conclusions all emphasize the need for more high-quality evidence-based primary research to optimize perioperative management of patients taking GLP-1 RAs. [8] (10.1186/s13741-026-00662-9)
  • [L4] This narrative review explores the mechanisms of action of GLP-1 agonists, their effects on bone health, and the implications of their use in perioperative patients undergoing orthopedic surgery, with an emphasis on spine surgery. [9] (10.1177/15563316261438492)
  • [L1] These findings suggest a potential benefit of GLP-1RA use for optimizing high-risk patients who have obesity or diabetes undergoing total joint arthroplasty. [10] (10.1016/j.arth.2025.09.054)
  • [L5] The paper concludes that while GLP-1 receptor agonists show potential to reduce postoperative complications in total joint arthroplasty, findings remain inconsistent, and further research is needed to clarify their impact on outcomes and establish perioperative management guidelines. [11] (10.1016/j.arth.2025.10.027)
  • [L1] Preoperative glucagon-like peptide-1 receptor agonist use may be linked to reduced readmission risk following joint arthroplasty, without evidence of increased postoperative medical harm. [12] (10.1016/j.arth.2025.11.036)
  • [L5] Semaglutide and other GLP-1 agonists may increase the number of eligible candidates for elective total joint arthroplasty by enabling weight loss and improving diabetic control, while also potentially reducing postoperative complications such as sepsis and prosthetic joint infections. [13] (10.1016/j.arth.2023.12.014)
  • [L4] Available observational evidence suggests that extended GLP-1 RA withholding, 24-hour clear liquid diets, and pre-procedural gastric POCUS may be associated with reduced residual gastric content in selected patient populations. [14] (10.7759/cureus.108216)
  • [L3] Perioperative GLP-1RA use was associated with a small yet statistically significant reduction in the odds of wound dehiscence following CTR and did not increase the odds of any other 90-day postoperative complications. [15] (10.1016/j.jhsg.2025.100746)
  • [L4] Current observational data suggest that perioperative GLP-1 RA use in patients undergoing total hip or knee arthroplasty is not associated with a consistent increase in short-term revision rates and may be associated with a reduced risk of postoperative infection. [16] (10.1186/s42836-026-00375-w)
  • [L1] Exenatide is the best option agent with regard to the risk of fracture. [17] (10.1007/s00198-018-4649-8)

References

[1] Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia. The Korean Journal of Internal Medicine. 2026. DOI: 10.3904/kjim.2025.277

[2] Glucagon-like Peptide-1 Agonists. JBJS Reviews. 2024. DOI: 10.2106/jbjs.rvw.23.00167

[3] GLP-1 agonists: a new hope for patients, a new challenge for anaesthetists. Anaesthesiology Intensive Therapy. 2025. DOI: 10.5114/ait/203167

[4] Impact of Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes in Arthroplasty: A Systematic Review. The Journal of Arthroplasty. 2025. DOI: 10.1016/j.arth.2025.07.015

[5] The Impact of Glucagon-Like Peptide-1 Agonists on Hip and Knee Arthroplasty and Perioperative Considerations. The Journal of Arthroplasty. 2024. DOI: 10.1016/j.arth.2023.12.002

[6] GLP-1 receptor agonist therapy is not associated with adverse events following shoulder surgery: a systematic review and meta-analysis. Journal of Shoulder and Elbow Surgery. 2026. DOI: 10.1016/j.jse.2025.12.005

[7] Periprocedural use of GLP-1 receptor agonists: ANZCA Clinical Practice Recommendations. ANZCA. 2025.

[8] Perioperative anesthesia management of GLP-1 receptor agonists: a systematic review of potential risks. Perioperative Medicine. 2026. DOI: 10.1186/s13741-026-00662-9

[9] GLP-1 Agonists in Orthopedic Surgery: A Narrative Review of Bone Health and Surgical Implications. HSS Journal. 2026. DOI: 10.1177/15563316261438492

[10] The Impact of Glucagon-Like Peptide-1 Receptor Agonist Use on Clinical Outcomes After Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of 346,899 Patients. The Journal of Arthroplasty. 2025. DOI: 10.1016/j.arth.2025.09.054

[11] Glucagon-Like Peptide-1 Receptor Agonists: Have We Found the Holy Grail for Total Joint Arthroplasty?. The Journal of Arthroplasty. 2025. DOI: 10.1016/j.arth.2025.10.027

[12] Glucagon-Like Peptide-1 Receptor Agonists, Readmission, and Postoperative Complications in Arthroplasty: A Systematic Review and Meta-Analysis. The Journal of Arthroplasty. 2025. DOI: 10.1016/j.arth.2025.11.036

[13] Semaglutide and Other GLP-1 Agonists: A Boon for the Arthroplasty Industry?. The Journal of Arthroplasty. 2024. DOI: 10.1016/j.arth.2023.12.014

[14] Peri-Procedural Fasting and Gastric Ultrasound Strategies in Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Users: A Systematic Review With Qualitative Synthesis. Cureus. 2026. DOI: 10.7759/cureus.108216

[15] Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release. Journal of Hand Surgery Global Online. 2025. DOI: 10.1016/j.jhsg.2025.100746

[16] Glucagon-like peptide-1 receptor agonists in total joint arthroplasty: a comprehensive systematic review of what orthopaedic surgeons should know. Arthroplasty. 2026. DOI: 10.1186/s42836-026-00375-w

[17] Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporosis International. 2018. DOI: 10.1007/s00198-018-4649-8

Mga kaugnayanAno ang ibig sabihin ng mga ito? →